Globenewswire·2025-09-17 16:29Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of Savara Inc. securities, alleging misleading statements regarding the company's Biologics License Application for MOLBREEVI, which may have impacted investors negatively during the specified Class Period from March 7, 2024, to May 23, 2025 [1][5]. Group 1: Lawsuit Details - The class action lawsuit claims that Savara Inc. made false and misleading statements about the MOLBREEVI Biologics License Application, indicating that it lacked sufficient information for FDA approval [5]. - The lawsuit suggests that the delay in regulatory approval for MOLBREEVI increased the likelihood that Savara would need to raise additional capital, which was not disclosed to investors [5]. - Investors who purchased Savara securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Next Steps for Investors - Investors interested in joining the class action can submit their information through the Rosen Law Firm's website or contact them directly for more details [3][6]. - A lead plaintiff is needed to represent the class, and interested parties must move the Court by November 7, 2025, to serve in this capacity [1][3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].